Literature DB >> 28703283

Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Pavlína Janovská1, Vítězslav Bryja1.   

Abstract

In this review, we discuss the intricate roles of the Wnt signalling network in the development and progression of mature B-cell-derived haematological malignancies, with a focus on chronic lymphocytic leukaemia (CLL) and related B-cell lymphomas. We review the current literature and highlight the differences between the β-catenin-dependent and -independent branches of Wnt signalling. Special attention is paid to the role of the non-canonical Wnt/planar cell polarity (PCP) pathway, mediated by the Wnt-5-receptor tyrosine kinase-like orphan receptor (ROR1)-Dishevelled signalling axis in CLL. This is mainly because the Wnt/PCP co-receptor ROR1 was found to be overexpressed in CLL and the Wnt/PCP pathway contributes to numerous aspects of CLL pathogenesis. We also discuss the possibilities of therapeutically targeting the Wnt signalling pathways as an approach to disrupt the crucial interaction between malignant cells and their micro-environment. We also advocate the need for research in this direction for other lymphomas, namely, diffuse large B-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma, Burkitt lymphoma and follicular lymphoma where the Wnt signalling pathway probably plays a similar role. LINKED ARTICLES: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2017        PMID: 28703283      PMCID: PMC5727250          DOI: 10.1111/bph.13949

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  126 in total

Review 1.  Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility.

Authors:  Jessica R K Seifert; Marek Mlodzik
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

Review 2.  Wnt/beta-catenin signaling in development and disease.

Authors:  Hans Clevers
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

Review 3.  Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.

Authors:  Gregory Lazarian; Romain Guièze; Catherine J Wu
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.

Authors:  F Linke; M Harenberg; M M Nietert; S Zaunig; F von Bonin; A Arlt; M Szczepanowski; H A Weich; S Lutz; C Dullin; P Janovská; M Krafčíková; L Trantírek; P Ovesná; W Klapper; T Beissbarth; F Alves; V Bryja; L Trümper; J Wilting; D Kube
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

5.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Authors:  Michael Hudecek; Thomas M Schmitt; Sivasubramanian Baskar; Maria Teresa Lupo-Stanghellini; Tetsuya Nishida; Tori N Yamamoto; Marie Bleakley; Cameron J Turtle; Wen-Chung Chang; Harvey A Greisman; Brent Wood; David G Maloney; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

6.  Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Authors:  Julio Delgado; Michael Doubek; Tycho Baumann; Jana Kotaskova; Stefano Molica; Pablo Mozas; Alfredo Rivas-Delgado; Fortunato Morabito; Sarka Pospisilova; Emili Montserrat
Journal:  Am J Hematol       Date:  2017-02-13       Impact factor: 10.047

7.  Conformational switching in ezrin regulates morphological and cytoskeletal changes required for B cell chemotaxis.

Authors:  Neetha Parameswaran; Ken Matsui; Neetu Gupta
Journal:  J Immunol       Date:  2011-02-21       Impact factor: 5.422

8.  ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Authors:  George F Widhopf; Bing Cui; Emanuela M Ghia; Liguang Chen; Karen Messer; Zhouxin Shen; Steven P Briggs; Carlo M Croce; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

9.  Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration.

Authors:  Daruka Mahadevan; James Choi; Laurence Cooke; Bram Simons; Christopher Riley; Thomas Klinkhammer; Rohit Sud; Sirisha Maddipoti; Sean Hehn; Harinder Garewal; Catherine Spier
Journal:  Hum Genomics Proteomics       Date:  2009-06-24

Review 10.  B Cells use Conserved Polarity Cues to Regulate Their Antigen Processing and Presentation Functions.

Authors:  Maria-Isabel Yuseff; Ana Maria Lennon-Duménil
Journal:  Front Immunol       Date:  2015-05-27       Impact factor: 7.561

View more
  18 in total

1.  Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.

Authors:  Huihuang Yan; Shulan Tian; Geffen Kleinstern; Zhiquan Wang; Jeong-Heon Lee; Nicholas J Boddicker; James R Cerhan; Neil E Kay; Esteban Braggio; Susan L Slager
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

2.  Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.

Authors:  Hanna Karvonen; Robert Perttilä; Wilhelmiina Niininen; Veera Hautanen; Harlan Barker; Astrid Murumägi; Caroline A Heckman; Daniela Ungureanu
Journal:  Oncogene       Date:  2019-01-10       Impact factor: 9.867

Review 3.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

4.  RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.

Authors:  Tomasz Radaszkiewicz; Michaela Nosková; Kristína Gömöryová; Olga Vondálová Blanářová; Katarzyna Anna Radaszkiewicz; Markéta Picková; Ráchel Víchová; Tomáš Gybeľ; Karol Kaiser; Lucia Demková; Lucia Kučerová; Tomáš Bárta; David Potěšil; Zbyněk Zdráhal; Karel Souček; Vítězslav Bryja
Journal:  Elife       Date:  2021-10-27       Impact factor: 8.140

5.  Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma.

Authors:  Anne S Boewe; Silke Wemmert; Philipp Kulas; Bernhard Schick; Claudia Götz; Selina Wrublewsky; Mathias Montenarh; Michael D Menger; Matthias W Laschke; Emmanuel Ampofo
Journal:  Biomedicines       Date:  2022-04-21

Review 6.  The WNT/β-catenin dependent transcription: A tissue-specific business.

Authors:  Simon Söderholm; Claudio Cantù
Journal:  WIREs Mech Dis       Date:  2020-10-21

7.  WNT signalling: mechanisms and therapeutic opportunities.

Authors:  Gunnar Schulte; Vitezslav Bryja
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

8.  Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.

Authors:  Xiaosheng Wu; Mary Stenson; Jithma Abeykoon; Kevin Nowakowski; Lianwen Zhang; Joshua Lawson; Linda Wellik; Ying Li; Jordan Krull; Kerstin Wenzl; Anne J Novak; Stephen M Ansell; Gail A Bishop; Daniel D Billadeau; Kah Whye Peng; Francis Giles; Daniel M Schmitt; Thomas E Witzig
Journal:  Blood       Date:  2019-05-17       Impact factor: 25.476

9.  WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.

Authors:  Senmin Chen; Xiuli Yuan; Huanli Xu; Meng Yi; Sixi Liu; Feiqiu Wen
Journal:  Med Sci Monit       Date:  2020-06-29

Review 10.  Wnt-5A/B Signaling in Hematopoiesis throughout Life.

Authors:  Marina Mastelaro de Rezende; Giselle Zenker Justo; Edgar Julian Paredes-Gamero; Reinoud Gosens
Journal:  Cells       Date:  2020-07-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.